WallStSmart

Dell Technologies Inc (DELL)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Dell Technologies Inc generates 997% more annual revenue ($134.00B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 6.3%. DELL appears more attractively valued with a PEG of 0.67. DELL earns a higher WallStSmart Score of 74/100 (B).

DELL

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 6.5Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.39

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DELL.

VRTXUndervalued (+52.4%)

Margin of Safety

+52.4%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DELL6 strengths · Avg: 9.7/10
Market CapQuality
$270.14B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
44.3%10/10

Every $100 of equity generates 44 in profit

Revenue GrowthGrowth
87.5%10/10

Revenue surging 87.5% year-over-year

EPS GrowthGrowth
282.5%10/10

Earnings expanding 282.5% YoY

Debt/EquityHealth
-22.1910/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.678/10

Growing faster than its price suggests

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$114.33B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

DELL3 concerns · Avg: 3.0/10
P/E RatioValuation
33.2x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

Altman Z-ScoreHealth
1.392/10

Distress zone — elevated risk

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

P/E RatioValuation
26.7x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DELL

The strongest argument for DELL centers on Market Cap, Return on Equity, Revenue Growth. Revenue growth of 87.5% demonstrates continued momentum. PEG of 0.67 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : DELL

The primary concerns for DELL are P/E Ratio, Profit Margin, Altman Z-Score.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

DELL profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

DELL carries more volatility with a beta of 1.38 — expect wider price swings.

DELL is growing revenue faster at 87.5% — sustainability is the question.

DELL generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

DELL scores higher overall (74/100 vs 68/100) and 87.5% revenue growth. VRTX offers better value entry with a 52.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dell Technologies Inc

TECHNOLOGY · COMPUTER HARDWARE · USA

Dell Technologies Inc. designs, develops, manufactures, markets, sells and supports information technology solutions, products and services worldwide. The company is headquartered in Round Rock, Texas.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?